Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion

Csáti, Anett; Tajti, János; Kuris, Anikó; Tuka, Bernadett; Edvinsson, Lars; Warfvinge, Karin

doi:10.1016/j.neuroscience.2011.10.055

Cited by 70 publications

(68 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PACAP-38 is widely distributed in many organs and is therefore implicated in various biological functions. In human and animal tissues, PACAP and its receptors have been detected in the sensory TRIG (Hou et al, 2003;Tajti et al, 1999) and the parasympathetic SPGs and otic ganglia (Csati et al, 2012a;Edvinsson et al, 2001;Uddman et al, 1999). Moreover, they are closely related to the vascular smooth muscles and are present at different levels of the CNS and PNS (Arimura, 2007;Moller et al, 1993;Mulder et al, 1994;Pettersson et al, 2004).…”

Section: Pacapmentioning

confidence: 99%

Migraine and neuropeptides

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Pacapmentioning

confidence: 99%

Migraine and neuropeptides

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Immunohistochemical studies have demonstrated the expression of PACAP in the parasympathetic and sensory ganglia [8,12,69], the human TNC and the C1 and C2 levels of the cervical spinal cord [70].…”

Section: Pituitary Adenylate Cyclase-activating Polypeptide Type 1 Rementioning

confidence: 99%

Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors

Tajti

Csáti

Vécsei

2014

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

In order to overcome the therapeutic insufficiency, a calcitonin gene-related peptide receptor antagonist without the side-effect of liver transaminase elevation is required. Another therapeutic option is to develop a neurally acting antimigraine agent, such as a serotonin-1F receptor agonist, with low adverse central nervous system events. Development of a potent dopamine receptor antagonist is necessary to diminish the premonitory symptoms of migraine. A further option is to decrease the headache intensity with a pituitary adenylate cyclase-activating polypeptide type 1 receptor blocker which can cross the blood-brain barrier. Finally, synthetic kynurenine analogues are required to block the pain transmission in the activated trigeminal system.

show abstract

“…Since the discovery in 1989, PACAP has been an object of intense anatomical, physiological and pharmacological studies. Using immunohistochemical and radioimmunoassay techniques, the expression of PACAP and its receptors has been found in numerous mammalian tissues including neurons of the central and peripheral nervous system (Masuo et al 1991, Ghatei et al 1993, Csati et al 2012, Rytel et al 2014 as well as enteric Liu 2001, Miampamba et al 2002) and intramural ganglia of the pancreas (Hannibal and Fahrenkrug 2000) and heart (Girard et al 2007). At the central level, PACAP may exert a variety of functions like modulation of hypothalamic-pituitary hormones release (Kanasaki et al 2015), food consumption and water drinking (Puig de Parada et al 1995, Mounien et al 2009), neuronal differentiation, neuroprotection (Manecka et al 2013) and many more, whereas its role at the periphery is relatively less understood.…”

Section: Introductionmentioning

confidence: 99%

Pituitary adenylate cyclase-activating peptide-27 (PACAP-27) is co-stored with galanin, substance P and corticotropin releasing factor (CRF) in intrapancreatic ganglia of the sheep

Arciszewski¹,

Mozel²,

Sienkiewicz³

2015

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide existing in two variant forms (of either 27 or 38 residues), widely present in numerous organs and evoking multiple effects both in the central and peripheral nervous systems. The present study was undertaken to evaluate the distribution pattern of PACAP-27 expression in the ovine pancreas. Using double immunohistochemical stainings co-localizations of PACAP-27 with galanin, SP or CRF were studied in intrapancreatic neurons. In intrapancreatic ganglia, immunoreactivty to PACAP-27 was found in 87.6 ± 5.4% of PGP 9.5-positive intrapancreatic neurons but not in intraganglionic nerve fibres. Numerous PACAP-27-immunoreactive nerve terminals were also observed between pancreatic acini and around small arterioles. No immunoreactivity to PACAP-27 was found in the endocrine pancreas. In 42.9 ± 6.2% of PACAP-27-immunoreactive intrapancreatic neurons the expression of galanin was also found. Statistically lower subpopulation (12.4 ± 4.0%) of intrapancreatic neurons exhibited simultaneously the immunoreactivity to PACAP-27 and SP. The expression of CRF was detected in the relatively smallest group (3.2 ± 1.4%) of PACAP-27-positive intrapancreatic neurons. The present results suggest that in the ovine pancreas PACAP-27 may play an important role as mediator of pancreatic functions. In PACAP-related pancreatic activities, a modulatory role of galanin, SP and to a lower extend of CRF is also likely.

show abstract

Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion

Cited by 70 publications

References 51 publications

Migraine and neuropeptides

Migraine and neuropeptides

Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors

Pituitary adenylate cyclase-activating peptide-27 (PACAP-27) is co-stored with galanin, substance P and corticotropin releasing factor (CRF) in intrapancreatic ganglia of the sheep

Contact Info

Product

Resources

About